English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background: Dyslipidemia is the commonest cause of the cardiovascular diseases and increases mortality worldwide. It leads to disturbance in the range of Total Cholesterol, LDL-C, VLDL and HDL-C in the plasma of dyslipidemic patients. Most of the studies relating to the effectiveness of Rosuvastatin and Fenofibrate have been conducted in the western countries and scant attention has been paid to examine the effectiveness of these drugs on the people of South Asian countries. The present study is an effort to focus on the effectiveness of these drugs on the people of Majha region of Punjab, India.Aim:Â  To see the effects of both drugs as monotherapy on the various parameters of lipid profile and goals achieved according to NCEP-ATP III guidelines in North Indian population.Material and Methods: This was a randomized, open label, parallel study conducted to assess the effect of rosuvastatin 10 mg and fenofibrate 160 mg daily for 12 weeks in newly diagnosed dyslipidemic patients (n=60). Patients were evaluated at day 0 and at 6 and 12 weeks.Results:At 6 weeks there were falls for Total cholesterol by 20.41% vs.Â  15.64% (p< 0.001, both), triglycerides 16.21% vs. 19.85% (p< 0.001, both) and LDL-C 27.47% vs. 21.43% (p< 0.001, both) respectively with rosuvastatin and fenofibrate from baseline. And at 12 weeks plasma levels continued to fall for Total cholesterol by 35.79% vs.Â  25.60% (p< 0.001, both), triglycerides 29.30% vs. 39.92% (p< 0.001, both), LDL-C 47.82% vs. 34.67% (p< 0.001, both), and there was rise of HDL-C levels by 18.75% vs. 30.53% (p< 0.001, both) respectively with rosuvastatin and fenofibrate. Both the agents achieved desired goals of NCEP-ATP III for Total Cholesterol, Triglyceride, LDL, HDL and also treat the metabolic syndrome (by 39.22% and 42.66% respectively) patients.Conclusion: Rosuvastatin and Fenofibrate monotherapy in patients with dyslipidemia effectively improved the Lipid profile as both these agents have had achieved the desired goal to treat the components of metabolic syndrome and other NCEP-ATP III targets. Key words: Dyslipidemia, Metabolic syndrome, NCEP-ATP III goals, Fenofibrate and Rosuvastatin.

A Comparative study of Rosuvastatin and Fenofibrate as Monotherapy in Dyslipidemia and NCEP ATP III Goals